AgeX Therapeutics, Inc. is a biotechnology company that was formed in 2017 and is a subsidiary of BioTime, Inc. Its focus is on applying cell immortalization and pluripotency technology to age-related diseases.
AgeX scientists believe that a combination of telomerase therapy and their proprietary induced tissue regeneration (iTR) technology may unlock the potential for potent tissue regeneration in humans, much like certain species of animal naturally enjoy.
Some animals, such as the Mexican salamander, can regenerate damaged tissues at a profound rate. Humans also have the potential to do the same, but for us, this only happens during the first weeks of our development. We have the ability to regenerate just the same as the salamander does, but it is locked away in our cells.
Using the power of machine learning and advanced molecular technologies, AgeX has identified the key pathways that could potentially unlock this innate potent regenerative potential in adults.
What is more, these pathways also appear to be instrumental in the aging process as well as cancer. This should be no surprise, as regeneration, aging, and cancer are entwined in a complex biological dance of sorts.
The iTR technology is currently in animal studies and is on the path towards human clinical trials.